Trials / Completed
CompletedNCT04713930
A Study of JNJ-61393215 in Healthy Japanese Male Participants
A Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-61393215 in Healthy Japanese Adult Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Janssen Pharmaceutical K.K. · Industry
- Sex
- Male
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) after single dose administrations of JNJ-61393215 in Japanese healthy adult male participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-61393215 | JNJ-61393215 will be administered orally. |
| DRUG | Placebo | Placebo will be administered orally. |
Timeline
- Start date
- 2021-01-29
- Primary completion
- 2021-05-31
- Completion
- 2021-05-31
- First posted
- 2021-01-19
- Last updated
- 2025-04-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04713930. Inclusion in this directory is not an endorsement.